- Adagio Therapeutics Inc’s ADGI Part 2/3 trials evaluating 300 mg adintrevimab (ADG20) as pre-and-post-exposure prophylaxis (EVADE) and therapy (STAMP) for COVID-19 have met its major endpoints.
- Following the emergence of the omicron variant, a pre-specified exploratory evaluation in a subset of the pre-exposure cohort, adintrevimab exhibited a clinically significant discount in instances of symptomatic COVID-19 in comparison with placebo.
- The chance of symptomatic COVID-19 was lowered by 71% in comparison with placebo in pre-exposure prophylaxis and 75% in post-exposure prophylaxis.
- Within the STAMP examine, adintrevimab demonstrated a 66% relative danger discount. One dying (0.6%) was within the adintrevimab group, in contrast with six deaths (3.6%) within the placebo group.
- Associated: Adagio Lays Out Growth Plans For COVID-19-Targeted ADG20 Program.
- In sufferers handled inside three days of symptom onset, adintrevimab lowered the chance of COVID-19 hospitalization or dying by 77% in comparison with placebo.
- Adagio plans to submit an FDA Emergency Use Authorization software in Q2 of 2022 for adintrevimab to stop and deal with COVID-19.
- As well as, preliminary security knowledge via two weeks post-dosing recommend a good security profile on the 1200mg dose.
- Re-engineered variants of ADG20 present over 100-fold enchancment in binding and as much as 40-fold enhanced neutralizing exercise towards the omicron BA.1 variant whereas sustaining exercise towards all different variants of concern.
- Adagio closed 2021 with money, money equivalents, and marketable securities of $591.4 million, enough to fund its bills into the 2H of 2024.
- Value Motion: ADGI shares 45.70% at $5.61 throughout the market session on the final test Wednesday.
© 2022 Benzinga.com. Benzinga doesn’t present funding recommendation. All rights reserved.
